Idera Pharmaceuticals Inc logo

IDRA - Idera Pharmaceuticals Inc Share Price

$2.22 -0.1  -5.1%

Last Trade - 29/09/20

Small Cap
Market Cap £64.2m
Enterprise Value £40.0m
Revenue £n/a
Position in Universe 4449th / 6407
Unlock IDRA Revenue
Relative Strength (%)
1m +17.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.073 0.25 16.2 0.90 0.66 1.45 +81.8%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Idera Pharmaceuticals Inc revenues decreased from $1.4M to $0K. Net loss decreased 30% to $15.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Restructuring costs decrease from $176K (expense) to $0K, Foreign currency exchange gain (loss) increase from $1K (expense) to $52K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IDRA Revenue Unlock IDRA Revenue

Net Income

IDRA Net Income Unlock IDRA Revenue

Normalised EPS

IDRA Normalised EPS Unlock IDRA Revenue

PE Ratio Range

IDRA PE Ratio Range Unlock IDRA Revenue

Dividend Yield Range

IDRA Dividend Yield Range Unlock IDRA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IDRA EPS Forecasts Unlock IDRA Revenue
Profile Summary

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated August 24, 2005
Public Since January 11, 1999
No. of Shareholders: 57
No. of Employees: 36
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 35,199,246
Free Float (0.0%)
Eligible for
IDRA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IDRA
Upcoming Events for IDRA
Frequently Asked Questions for Idera Pharmaceuticals Inc
What is the Idera Pharmaceuticals Inc share price?

As of 29/09/20, shares in Idera Pharmaceuticals Inc are trading at $2.22, giving the company a market capitalisation of £64.2m. This share price information is delayed by 15 minutes.

How has the Idera Pharmaceuticals Inc share price performed this year?

Shares in Idera Pharmaceuticals Inc are currently trading at $2.22 and the price has moved by -10.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Idera Pharmaceuticals Inc price has moved by -19.09% over the past year.

What are the analyst and broker recommendations for Idera Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Idera Pharmaceuticals Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Idera Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Idera Pharmaceuticals Inc next release its financial results?

Idera Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Idera Pharmaceuticals Inc dividend yield?

Idera Pharmaceuticals Inc does not currently pay a dividend.

Does Idera Pharmaceuticals Inc pay a dividend?

Idera Pharmaceuticals Inc does not currently pay a dividend.

When does Idera Pharmaceuticals Inc next pay dividends?

Idera Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Idera Pharmaceuticals Inc shares?

To buy shares in Idera Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Idera Pharmaceuticals Inc?

Shares in Idera Pharmaceuticals Inc are currently trading at $2.22, giving the company a market capitalisation of £64.2m.

Where are Idera Pharmaceuticals Inc shares listed? Where are Idera Pharmaceuticals Inc shares listed?

Here are the trading details for Idera Pharmaceuticals Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: IDRA
What kind of share is Idera Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Idera Pharmaceuticals Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Idera Pharmaceuticals Inc share price forecast 2020?

Shares in Idera Pharmaceuticals Inc are currently priced at $2.22. At that level they are trading at 0.225% discount to the analyst consensus target price of 0.00.

Analysts covering Idera Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.922 for the next financial year.

How can I tell whether the Idera Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Idera Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 40.05%. At the current price of $2.22, shares in Idera Pharmaceuticals Inc are trading at 28.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Idera Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Idera Pharmaceuticals Inc.

Who are the key directors of Idera Pharmaceuticals Inc?

Idera Pharmaceuticals Inc's management team is headed by:

james Geraghty - CHM
Mark Goldberg - IND
Vincent Milano - PRE
Robert Fletcher - SVP
Maxine Gowen - IND
Bryant Lim - SVP
John Kirby - CFO
Carol Schafer - IND
Cristina Csimma - IND
Michael Dougherty - IND
Elizabeth Tarka - SVP
Who are the major shareholders of Idera Pharmaceuticals Inc?

Here are the top five shareholders of Idera Pharmaceuticals Inc based on the size of their shareholding:

Pillar Pharmaceuticals I, L.P. Corporation
Percentage owned: 19.36% (6.81m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 13.09% (4.61m shares)
Castellina Ventures, Ltd. Corporation
Percentage owned: 6.39% (2.25m shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 2.93% (1.03m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.82% (992k shares)
Similar to IDRA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.